The ARUBA trial

Current status, future hopes

J. P. Mohr, Alan J. Moskowitz, Christian Stapf, Andreas Hartmann, Karen Lord, Steven M. Marshall, Henning Mast, Ellen Moquete, Claudia Scala Moy, Michael K. Parides, John Pile-Spellman, Rustam Al-Shahi Salman, Alan Weinberg, William L. Young, Alejandrina Estevez, Inam Kureshi, Jonathan L. Brisman

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

Background and Purpose-: Report on the status of an on-going National Institutes of Neurological Disorders and Stroke (NINDS)-supported clinical trial of management of unbled brain arteriovenous malformations. Summary of Review-: Begun in April 2007 with 3 centers, the trial has grown to 65 centers, and has randomized 124 patients through mid-June 2010 en route to the planned 400. The current literature continues to support the rationale for the trial. Conclusions-: ARUBA is steadily approaching its monthly randomization goals and has already reached the number needed to test the maximum published interventional complication rates against the minimum hemorrhage rates for natural history.

Original languageEnglish (US)
JournalStroke
Volume41
Issue number8
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

National Institute of Neurological Disorders and Stroke
Arteriovenous Malformations
Random Allocation
Natural History
Clinical Trials
Hemorrhage
Brain

Keywords

  • arteriovenous malformations
  • endovascular treatment
  • neuroradiology
  • neurosurgery
  • radiotherapy
  • randomized controlled trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Mohr, J. P., Moskowitz, A. J., Stapf, C., Hartmann, A., Lord, K., Marshall, S. M., ... Brisman, J. L. (2010). The ARUBA trial: Current status, future hopes. Stroke, 41(8). https://doi.org/10.1161/STROKEAHA.110.580274

The ARUBA trial : Current status, future hopes. / Mohr, J. P.; Moskowitz, Alan J.; Stapf, Christian; Hartmann, Andreas; Lord, Karen; Marshall, Steven M.; Mast, Henning; Moquete, Ellen; Moy, Claudia Scala; Parides, Michael K.; Pile-Spellman, John; Al-Shahi Salman, Rustam; Weinberg, Alan; Young, William L.; Estevez, Alejandrina; Kureshi, Inam; Brisman, Jonathan L.

In: Stroke, Vol. 41, No. 8, 01.08.2010.

Research output: Contribution to journalReview article

Mohr, JP, Moskowitz, AJ, Stapf, C, Hartmann, A, Lord, K, Marshall, SM, Mast, H, Moquete, E, Moy, CS, Parides, MK, Pile-Spellman, J, Al-Shahi Salman, R, Weinberg, A, Young, WL, Estevez, A, Kureshi, I & Brisman, JL 2010, 'The ARUBA trial: Current status, future hopes', Stroke, vol. 41, no. 8. https://doi.org/10.1161/STROKEAHA.110.580274
Mohr JP, Moskowitz AJ, Stapf C, Hartmann A, Lord K, Marshall SM et al. The ARUBA trial: Current status, future hopes. Stroke. 2010 Aug 1;41(8). https://doi.org/10.1161/STROKEAHA.110.580274
Mohr, J. P. ; Moskowitz, Alan J. ; Stapf, Christian ; Hartmann, Andreas ; Lord, Karen ; Marshall, Steven M. ; Mast, Henning ; Moquete, Ellen ; Moy, Claudia Scala ; Parides, Michael K. ; Pile-Spellman, John ; Al-Shahi Salman, Rustam ; Weinberg, Alan ; Young, William L. ; Estevez, Alejandrina ; Kureshi, Inam ; Brisman, Jonathan L. / The ARUBA trial : Current status, future hopes. In: Stroke. 2010 ; Vol. 41, No. 8.
@article{4e5c860289da4bc88714677d9c0027a6,
title = "The ARUBA trial: Current status, future hopes",
abstract = "Background and Purpose-: Report on the status of an on-going National Institutes of Neurological Disorders and Stroke (NINDS)-supported clinical trial of management of unbled brain arteriovenous malformations. Summary of Review-: Begun in April 2007 with 3 centers, the trial has grown to 65 centers, and has randomized 124 patients through mid-June 2010 en route to the planned 400. The current literature continues to support the rationale for the trial. Conclusions-: ARUBA is steadily approaching its monthly randomization goals and has already reached the number needed to test the maximum published interventional complication rates against the minimum hemorrhage rates for natural history.",
keywords = "arteriovenous malformations, endovascular treatment, neuroradiology, neurosurgery, radiotherapy, randomized controlled trials",
author = "Mohr, {J. P.} and Moskowitz, {Alan J.} and Christian Stapf and Andreas Hartmann and Karen Lord and Marshall, {Steven M.} and Henning Mast and Ellen Moquete and Moy, {Claudia Scala} and Parides, {Michael K.} and John Pile-Spellman and {Al-Shahi Salman}, Rustam and Alan Weinberg and Young, {William L.} and Alejandrina Estevez and Inam Kureshi and Brisman, {Jonathan L.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1161/STROKEAHA.110.580274",
language = "English (US)",
volume = "41",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The ARUBA trial

T2 - Current status, future hopes

AU - Mohr, J. P.

AU - Moskowitz, Alan J.

AU - Stapf, Christian

AU - Hartmann, Andreas

AU - Lord, Karen

AU - Marshall, Steven M.

AU - Mast, Henning

AU - Moquete, Ellen

AU - Moy, Claudia Scala

AU - Parides, Michael K.

AU - Pile-Spellman, John

AU - Al-Shahi Salman, Rustam

AU - Weinberg, Alan

AU - Young, William L.

AU - Estevez, Alejandrina

AU - Kureshi, Inam

AU - Brisman, Jonathan L.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Background and Purpose-: Report on the status of an on-going National Institutes of Neurological Disorders and Stroke (NINDS)-supported clinical trial of management of unbled brain arteriovenous malformations. Summary of Review-: Begun in April 2007 with 3 centers, the trial has grown to 65 centers, and has randomized 124 patients through mid-June 2010 en route to the planned 400. The current literature continues to support the rationale for the trial. Conclusions-: ARUBA is steadily approaching its monthly randomization goals and has already reached the number needed to test the maximum published interventional complication rates against the minimum hemorrhage rates for natural history.

AB - Background and Purpose-: Report on the status of an on-going National Institutes of Neurological Disorders and Stroke (NINDS)-supported clinical trial of management of unbled brain arteriovenous malformations. Summary of Review-: Begun in April 2007 with 3 centers, the trial has grown to 65 centers, and has randomized 124 patients through mid-June 2010 en route to the planned 400. The current literature continues to support the rationale for the trial. Conclusions-: ARUBA is steadily approaching its monthly randomization goals and has already reached the number needed to test the maximum published interventional complication rates against the minimum hemorrhage rates for natural history.

KW - arteriovenous malformations

KW - endovascular treatment

KW - neuroradiology

KW - neurosurgery

KW - radiotherapy

KW - randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=77955171681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955171681&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.110.580274

DO - 10.1161/STROKEAHA.110.580274

M3 - Review article

VL - 41

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -